Head And Neck Cancer - Pipeline Review, H2 2011

Global Markets Direct, September 2011, Pages: 280

Head And Neck Cancer - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Head and Neck Cancer - Pipeline Review, H2 2011', provides an overview of the Head and Neck Cancer therapeutic pipeline. This report provides information on the therapeutic development for Head and Neck Cancer , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head and Neck Cancer . 'Head and Neck Cancer - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Head and Neck Cancer .
- A review of the Head and Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Head and Neck Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Head and Neck Cancer .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Head and Neck Cancer pipeline depth and focus of Head and Neck Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Head And Neck Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Head And Neck Cancer
Head And Neck Cancer Therapeutics under Development by Companies
Head And Neck Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Head And Neck Cancer Therapeutics - Products under Development by Companies
Head And Neck Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Head And Neck Cancer Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Vical Incorporated
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
GenVec, Inc.
YM BioSciences Inc.
Light Sciences Oncology, Inc.
Bio-Path Holdings, Inc.
Aposense Ltd.
Millennium Pharmaceuticals, Inc.
Novartis AG
ImClone Systems Incorporated
OSI Pharmaceuticals, Inc.
Pfizer Inc.
Takara Holdings Inc.
Genmab A/S
Cyclacel Pharmaceuticals Inc.
CEL-SCI Corporation
Quintiles Transnational Corp.
Introgen Therapeutics, Inc.
SRI International
Merck KGaA
Advaxis, Inc.
Neogenix Oncology Corporation
InNexus Biotechnology Inc.
MethylGene Inc
Bionomics Limited
Northwest Biotherapeutics, Inc.
Cleveland BioLabs, Inc.
Oncolytics Biotech Inc.
Oncothyreon Inc
Curis, Inc.
ARQULE, INC
ADVENTRX Pharmaceuticals
Pharmacyclics, Inc.
Transgene SA
TapImmune Inc.
Sareum Holdings plc
PCI Biotech AS
Piramal Life Sciences Limited
Wilex AG
Glycotope GmbH
Boneca Corporation
Biotech Pharmaceuticals Co., Ltd.
CytomX, LLC.
Head And Neck Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Zalutumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Multikine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AdhTAP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kevetrin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Advexin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tykerb - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tirazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tarceva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alimta + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nimotuzumab + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Multikine + Cyclophosphamide + Indomethacin + Zinc - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Multikine + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Head And Neck Cancer Therapeutics – Drug Profile Updates
Head And Neck Cancer Therapeutics - Discontinued Products
Head And Neck Cancer - Featured News
Aug 23, 2011: Symphogen Initiates Phase II Trial Of Sym004 EGFR Antibody Mixture In Patients With Squamous Cell Carcinoma Of Head And Neck Cancer
Aug 18, 2011: CEL-SCI Addresses Warning Letter In Regard To Statements On Corporate Website
Aug 17, 2011: CEL-SCI Receives Chinese Patent For Investigational Cancer Therapy Multikine
Aug 16, 2011: Curis Announces Dosing Of First Patient In Phase I CUDC-101 Head And Neck Cancer Combination Trial
Jul 07, 2011: Idera Pharmaceuticals Provides Update On IMO-2055 Clinical Development Program
Jul 07, 2011: Idera Pharmaceuticals Provides Update On IMO-2055 Clinical Development Program
Jun 27, 2011: CEL-SCI Announces Start Of Multikine Phase III Study By Teva, In Israel
Jun 24, 2011: PCI Biotech Announces Main Results Of Full Phase I/II Study Of Amphinex
Jun 24, 2011: Genmab Announces Zalutumumab Update
Jun 23, 2011: CEL-SCI Announces Start Of Multikine Phase III Study By Orient Europharma In Taiwan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Head And Neck Cancer, H2 2011
Products under Development for Head And Neck Cancer – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Bristol-Myers Squibb Company, H2 2011
Johnson & Johnson, H2 2011
Boehringer Ingelheim GmbH, H2 2011
F. Hoffmann-La Roche Ltd., H2 2011
Kyowa Hakko Kirin Co., Ltd., H2 2011
Vical Incorporated, H2 2011
Amgen Inc., H2 2011
Sanofi-Aventis, H2 2011
AstraZeneca PLC, H2 2011
Eli Lilly and Company, H2 2011
Viralytics Ltd., H2 2011
GlaxoSmithKline plc, H2 2011
GenVec, Inc., H2 2011
YM BioSciences Inc., H2 2011
Light Sciences Oncology, Inc., H2 2011
Bio-Path Holdings, Inc., H2 2011
Aposense Ltd., H2 2011
Millennium Pharmaceuticals, Inc., H2 2011
Novartis AG, H2 2011
ImClone Systems Incorporated, H2 2011
OSI Pharmaceuticals, Inc., H2 2011
Pfizer Inc., H2 2011
Takara Holdings Inc., H2 2011
Genmab A/S, H2 2011
Cyclacel Pharmaceuticals Inc., H2 2011
CEL-SCI Corporation, H2 2011
Quintiles Transnational Corp., H2 2011
Introgen Therapeutics, Inc., H2 2011
SRI International, H2 2011
Merck KGaA, H2 2011
Advaxis, Inc., H2 2011
Neogenix Oncology Corporation, H2 2011
InNexus Biotechnology Inc., H2 2011
MethylGene Inc, H2 2011
Bionomics Limited, H2 2011
Northwest Biotherapeutics, Inc., H2 2011
Cleveland BioLabs, Inc., H2 2011
Oncolytics Biotech Inc., H2 2011
Oncothyreon Inc, H2 2011
Curis, Inc., H2 2011
ARQULE, INC, H2 2011
ADVENTRX Pharmaceuticals, H2 2011
Pharmacyclics, Inc., H2 2011
Transgene SA, H2 2011
TapImmune Inc., H2 2011
Sareum Holdings plc, H2 2011
PCI Biotech AS, H2 2011
Piramal Life Sciences Limited, H2 2011
Wilex AG, H2 2011
Glycotope GmbH, H2 2011
Matrix Pharmaceutical Research, H2 2011
Hawthorn Pharmaceuticals, Inc., H2 2011
PDS Biotechnology Corporation, H2 2011
Azaya Therapeutics, Inc., H2 2011
Innogene Kalbiotech Pte Ltd., H2 2011
Vaccinogen, Inc., H2 2011
Oncolys BioPharma Inc., H2 2011
Etubics Corporation, H2 2011
Viventia Biotechnologies Inc., H2 2011
IRX Therapeutics, Inc., H2 2011
Pique Therapeutics, H2 2011
Cellceutix Pharmaceuticals, Inc., H2 2011
PNP Therapeutics, Inc., H2 2011
TAU Therapeutics, LLC, H2 2011
Boneca Corporation, H2 2011
Biotech Pharmaceuticals Co., Ltd., H2 2011
CytomX, LLC., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Head And Neck Cancer Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Head And Neck Cancer, H2 2011
Products under Development for Head And Neck Cancer – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Head And Neck Cancer - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Prostate Cancer - Pipeline Review, H2 2012
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Metastatic Colorectal Cancer - Pipeline Review, H2 2012